Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases
source: Transfusion
year: 2015
authors: Santos B, Portugal R, Nogueira C, Loureiro M
summary/abstract:BACKGROUND:
Sickle cell anemia (SCA) is characterized by chronic hemolytic anemia. Worsening of anemia after red blood cell (RBC) transfusion has been reported and is often referred to as hyperhemolysis syndrome (HS). HS is a severe transfusion reaction characterized by destruction of both donor and host RBCs.
CASE REPORTS:
In this study we report the clinical findings and treatment of three adolescent patients with SCA who presented with HS. HS occurred after exchange transfusion in two cases and after RBC transfusion during vasoocclusive crises in one. A decrease of serum hemoglobin (Hb) levels was observed 5 to 7 days after transfusions and ranged from 2.5 to 5.7 g/dL. The direct antiglobulin test was positive in two patients who also presented with alloantibodies. Patient 3 received 2 additional RBC units after the onset of HS and experienced the lowest Hb values (2.5 g/dL) shortly after. Patients received intravenous steroids as the main specific treatment and also immunoglobulin and erythropoietin. Resolution of hemolysis was observed in all cases. Of note, spleen lesions were detected in two patients, one had a normal spleen size, and the other presented with enlarged spleen. Pathophysiologic implications of these findings were discussed.
CONCLUSIONS:
HS must be a well-recognized complication of SCA after RBC transfusion. Prompt initiation of treatment and avoiding further transfusions may contribute to reduce the mortality associated with HS. The presence of functional spleen on the pathophysiology of HS deserves further evaluation.
DOI: 10.1111/trf.12993
read more full text
+myBinderRelated Content
-
Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic sy...The risk and clinical significance of ca...
-
The Association Between Timely Opioid Administration and Hospitalization in Children With Sickle Cell Disease Presen...Objective: To evaluate the association ...
-
Siklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
-
Genetic Treatments for Sickle CellFor decades physicians have known that a...
-
MARAC Statement: Crizanlizumab (Adakveo)July 7, 2023 - SCDAA’s Medical and Res...
-
SCDAA Masterclass Speaker Series: All Things Considered – SCD Treatment: A Personal ChoiceSCDAA's First Masterclass on the Cusp of...
-
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.